Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRTCOESC: Capecitabine vs. Cisplatin/5-FU in Esophageal Cancer
NCT02025036Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Oct 2014
- Primary completion
- Sep 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Status: unknown.
02
Drugs
capecitabine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02025036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025036.